

University of Dundee

Isotretinoin and mental health

Affleck, A.; Stewart, M.; Nicolson, J.; Salmon, N.

Published in:
Clinical and Experimental Dermatology

DOI:
[10.1111/ced.14140](https://doi.org/10.1111/ced.14140)

Publication date:
2020

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):
Affleck, A., Stewart, M., Nicolson, J., & Salmon, N. (2020). Isotretinoin and mental health: a survey of Scottish Dermatology Society members. *Clinical and Experimental Dermatology*, 45(4), 476-478.
<https://doi.org/10.1111/ced.14140>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

DR ANDREW GRAEME AFFLECK (Orcid ID : 0000-0002-0385-3186)

Article type : Correspondence

Corresponding author email id : andrew.affleck@nhs.net

Isotretinoin and mental health; a survey of Scottish Dermatology Society members

A. Affleck,¹ M. Stewart,² J. Nicolson³ and N. Salmon¹

¹*Department of Dermatology, Ninewells Hospital, NHS Tayside, Dundee, UK;*

²*Liaison Psychiatry, Carseview Centre, Dundee, UK; and* ³*University of Dundee School of Medicine, Dundee, UK*

Daunton *et al* report a study exploring the practice of dermatologists prescribing isotretinoin in 4 different clinical scenarios with different degrees of theoretical risk of deterioration in emotional health / suicide.¹ The results show a degree of therapeutic timidity in some respondents which is to be expected and based on a number of variables including cognitive biases.² In May 2018 we recently surveyed members of the Scottish Dermatology Society (SDS) using survey-monkey® to assess their perception and experience of mood disturbance in patients taking isotretinoin for acne. We received 48 respondents (32 of which were Consultant Dermatologists (67% of total respondents)). The SDS membership is fluid but at the time of the survey there were 314 members of which 118 were Consultant Dermatologists. Not all members are clinicians. A conservative estimated response rate therefore was

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/CED.14140](https://doi.org/10.1111/CED.14140)

This article is protected by copyright. All rights reserved

48/314 = 15%. 38% of respondents did not believe that isotretinoin can cause depression; however, 71% admit to worrying about patients' mental health and 87% had stopped isotretinoin due to concern about mental health. Self-rated confidence in dermatologists' ability to perform a psychiatric assessment varied with only 6% feeling extremely or very confident, but only 25% used a questionnaire to aid mental wellbeing assessment. 29% ask about suicidal thoughts in every consultation and 71% ask only if signs of low mood were present. Reassuringly, only 2 respondents reported a completed suicide of a patient while taking isotretinoin in their career to date (out of an approximate cumulative total of 695 years of clinical practice of respondents). There are approximately 700 cases of completed suicide in Scotland per year of which 250 occur in young adults.³ We estimate the expected number of completed suicides for the number and age of patients seen to be 3.6 based on known population data for Scotland.³ Therefore, our findings would be in keeping with the reports from previous studies that have not found an increased prevalence of completed suicide associated with isotretinoin use although no firm conclusions can be made due to the limitations of our study.

We agree that using a validated screening questionnaire eg the HADS and / or PHQ-9 helps in assessment and monitoring of distress, depressive symptoms, anxiety and suicidal ideation. We also agree that referral to psychiatry is rarely indicated.

Some individuals are constitutionally predisposed to depression and suicidal ideation. Acne can be an independent risk factor for depression and this risk may increase with lack of effective treatment for acne eg withholding or delaying isotretinoin therapy. Isotretinoin is usually a highly effective treatment for acne and so can improve wellbeing and reduce suicide risk.⁴ However, in a minority of patients, isotretinoin appears to unmask depressive symptoms and suicidal

ideation. Unfortunately, no one can accurately predict suicide and no specific tests are capable of identifying a suicidal person. However, in the context of an individual with acne having isotretinoin we suggest that individuals may be more at risk if there is a disappointing response to treatment, recurrent acne requiring multiple courses of isotretinoin, first time suicidal thoughts whilst taking isotretinoin and a lack of improvement in wellbeing despite successful clearing of acne.⁵ Other skin-associated risk factors include a disproportionate appearance concern / acne dysmorphia⁶, and general risk factors eg. feelings of hopelessness, social isolation and co-existing physical illness. Bipolar disorder often deteriorates with isotretinoin in our experience and others and we suggest this is a caution.⁷ We agree that liaising with the GP and / or psychiatry is indicated in individual cases and more frequent follow-up. Clear communication is important and robust mechanisms should be in place should a crisis arise eg supplying emergency contact phone numbers.

References

1. Daunton A, Oyeboode F, Goulding JMR. Depression and the dermatologist: a critical analysis of contemporary isotretinoin prescribing practices. *Clin Exp Dermatol* 2019. doi: 10.1111/ced.13971
2. Zachariae H. Therapeutic timidity in dermatology. *J Am Acad Dermatol* 2001; **4**: 140-1.
3. <https://www.scotpho.org.uk/health-wellbeing-and-disease/suicide/data/scottish-trends/>
4. Droitcourt C, Nowak E, Rault C *et al*. Risk of suicide attempt associated with isotretinoin: a nationwide cohort and nested case-time-control study. *Int J Epidemiol*; 2019 May 16. Pii: dyz093. Doi: 10. 1093/ije/dyz093. [Epub ahead of print]
5. Sundstrom A, Alfredsson L, Sjolín-Forsberg G. Association of suicide attempts with acne and treatment with isotretinoin: retrospective Swedish cohort study. *BMJ* 2010; 341: c5812. Doi: 10.11136/bmj.c5812.
6. Cotterill JA, Cunliffe WJ. Suicide in dermatological patients. *Br J Dermatol* 1997; **137**: 246-50.
7. Schaffer LC, Schaffer CB, Hunter S *et al*. Psychiatric reactions to isotretinoin in patients with bipolar disorder. *J Affect Disord* 2010; **122**: 306-8.